Plain-English translation of NCT07453888 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called , delivered as a nasal spray, to see if it can help restore vision in people who have recently experienced sudden vision loss in one eye due to a condition called non-arteritic anterior ischemic optic neuropathy (NAION). About 272 adults will be randomly assigned to receive either the medication or a placebo spray, and researchers will compare how well each group recovers their vision over time.
NAION causes sudden, often permanent vision loss when blood flow to the optic nerve is cut off, and currently there are no proven treatments to restore sight. This medication may help by encouraging nerve cells to repair and regrow, potentially reversing or reducing vision loss.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the nasal spray or a placebo spray, and you will use it in both nostrils as instructed. You will visit the research center multiple times for eye exams and vision tests to see if the medication helps restore your sight. The study is designed so that neither you nor the researchers know which group you are in, which helps ensure fair results.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States